✨ Unlock Data Exports And Disclosure Access. Start Your 30-Day Free Trial Today →

CanSino Biologics Inc

Common Name
CanSino Biologics
Country
China (Mainland)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,105
Ticker
688185
Exchange
SHANGHAI STOCK EXCHANGE
Description
CanSino Biologics Inc. is a biotechnology company focused on developing, manufacturing, and commercializing high-quality vaccines for public health. Founded in Tianjin, China, the company is known for...

CanSino Biologics's GHG Emissions Data Preview

In 2023, CanSino Biologics completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).

However, CanSino Biologics has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)202320222021
2020 - 2017
Total Scope 1
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
b
0000000
Total Scope 2
Unspecified Calculation Method
Copy/Paste is a PRO feature.
a
0000000
Copy/Paste is a PRO feature.
b
0000000
Total Scope 3
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
b
0000000
Limited Data Preview
You are viewing a limited preview of CanSino Biologics’s GHG emissions dataset. The full dataset, available for download, includes Scope 1, 2, and 3 emissions with detailed category-level breakdowns, historical coverage back to 2020, and revenue-based intensity metrics for each scope.
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=688185&reporting_period=2024"

Verified Sources Behind CanSino Biologics’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore CanSino Biologics’s data sources below and access millions more through our Disclosure Search.

a. CanSino Biologics's ESG Report 2023
b. CanSino Biologics's ESG Report 2022

Insights into CanSino Biologics's Operational Emissions

In 2023, the total operational greenhouse gas (GHG) emissions of CanSino Biologics amounted to 37,294.91 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2022, the total operational greenhouse gas (GHG) emissions of CanSino Biologics increased by 22.21%, suggesting that the company faced challenges in reducing its emissions from its core operations.ab

CanSino Biologics's Scope 1 Emissions Over Time

202020212022202302.5 k5 k7.5 k10 ktCO2e+91%-30%-41%
  • Total Scope 1
  • Year-over-Year Change

What are CanSino Biologics's Scope 1 emissions?

In 2023, the total Scope 1 emissions of CanSino Biologics were 3,541.18 metric tons of CO₂ equivalent (tCO₂e).a

Has CanSino Biologics reduced its Scope 1 emissions over time?

Since 2020, CanSino Biologics's Scope 1 emissions have decreased by 21.57%, reflecting a declining long-term trend in Scope 1 emissions over time.ab

Compared to the previous year (2022), CanSino Biologics's Scope 1 emissions decreased by 41.37%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.ab

What are CanSino Biologics's Scope 2 emissions?

In 2023, CanSino Biologics reported Scope 2 greenhouse gas (GHG) emissions of 33,753.73 tCO₂e without specifying the calculation method.a

Has CanSino Biologics reduced its Scope 2 emissions over time?

Since 2020, CanSino Biologics's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 163.18%, reflecting a rising long-term trend in Scope 2 emissions over time.ab

Compared to the previous year (2022), CanSino Biologics's Scope 2 emissions (Unspecified Calculation Method) rose by 37.9% in 2023, suggesting that the company faced challenges in reducing emissions from purchased electricity and energyab

What methodology does CanSino Biologics use for Scope 2 reporting?

In 2023, CanSino Biologics reported its Scope 2 emissions using an unspecified methodology.a

CanSino Biologics's Scope 2 Emissions Over Time

202020212022202308.5 k17 k25.5 k34 ktCO2e
  • Total Scope 2 (Unspecified Calculation Method)

Insights into CanSino Biologics’s GHG Emissions Intensity Compared to Industry Peers

In 2023, CanSino Biologics reported Scope 1 greenhouse gas (GHG) emissions of 3,541.18 tCO₂e and total revenues of USD 49 millions. This translates into an emissions intensity of 72.91 tCO₂e per millions USD.a

CanSino Biologics's Scope 1 Emissions Intensity Compared to Peers

102002,00050,000500,000Scope 1 Emissions (tCO2e)5502002,00010,000Revenues (Millions of USD)CCHPADSDCSimcere Pharmaceutical GroupYear: 2023Scope 1: 4,997 tCO2eRevenue: $M 1,017Scope 1 Intensity: 4.91 tCO2e/$MWalvax BiotechnologyYear: 2024Scope 1: 7,643 tCO2eRevenue: $M 387Scope 1 Intensity: 19.77 tCO2e/$MCCCR Double-CraneYear: 2024Scope 1: 58,155 tCO2eRevenue: $M 1,536Scope 1 Intensity: 37.86 tCO2e/$MHumanwell Healthcare GroupYear: 2024Scope 1: 19,500 tCO2eRevenue: $M 3,485Scope 1 Intensity: 5.60 tCO2e/$MLuye Pharma GroupYear: 2023Scope 1: 10,755 tCO2eRevenue: $M 945Scope 1 Intensity: 11.38 tCO2e/$MLivzon Pharmaceutical GroupYear: 2024Scope 1: 194,441 tCO2eRevenue: $M 1,619Scope 1 Intensity: 120.13 tCO2e/$MCCChangchun High-TechYear: 2023Scope 1: 61,590 tCO2eRevenue: $M 2,050Scope 1 Intensity: 30.05 tCO2e/$MHansoh Pharmaceutical GroupYear: 2024Scope 1: 13,163 tCO2eRevenue: $M 1,830Scope 1 Intensity: 7.19 tCO2e/$MHHHuadong MedicineYear: 2024Scope 1: 15,595 tCO2eRevenue: $M 5,742Scope 1 Intensity: 2.72 tCO2e/$MJoincareYear: 2024Scope 1: 197,854 tCO2eRevenue: $M 2,140Scope 1 Intensity: 92.45 tCO2e/$MPPPorton Pharma SolutionsYear: 2024Scope 1: 18,865 tCO2eRevenue: $M 413Scope 1 Intensity: 45.71 tCO2e/$MBioKangtaiYear: 2023Scope 1: 15,952 tCO2eRevenue: $M 489Scope 1 Intensity: 32.60 tCO2e/$MZhejiang Jiuzhou PharmaceuticalYear: 2023Scope 1: 48,815 tCO2eRevenue: $M 777Scope 1 Intensity: 62.81 tCO2e/$MYunnan Baiyao GroupYear: 2024Scope 1: 15,079 tCO2eRevenue: $M 5,485Scope 1 Intensity: 2.75 tCO2e/$MConsun Pharmaceutical GroupYear: 2023Scope 1: 54,210 tCO2eRevenue: $M 398Scope 1 Intensity: 136.27 tCO2e/$MAAApeloa PharmaceuticalYear: 2024Scope 1: 10,400 tCO2eRevenue: $M 1,647Scope 1 Intensity: 6.31 tCO2e/$MDDDong-E-E-JiaoYear: 2023Scope 1: 15,659 tCO2eRevenue: $M 663Scope 1 Intensity: 23.60 tCO2e/$MFosun PharmaYear: 2024Scope 1: 184,016 tCO2eRevenue: $M 5,627Scope 1 Intensity: 32.70 tCO2e/$MJiangsu Hengrui PharmaceuticalsYear: 2024Scope 1: 8,517 tCO2eRevenue: $M 3,835Scope 1 Intensity: 2.22 tCO2e/$MSSSihuan PharmaceuticalYear: 2023Scope 1: 45,602 tCO2eRevenue: $M 286Scope 1 Intensity: 159.27 tCO2e/$MTasly Pharmaceutical GroupYear: 2024Scope 1: 37,370 tCO2eRevenue: $M 1,164Scope 1 Intensity: 32.09 tCO2e/$MHua MedicineYear: 2023Scope 1: 19 tCO2eRevenue: $M 12Scope 1 Intensity: 1.63 tCO2e/$MHepalinkYear: 2024Scope 1: 18,284 tCO2eRevenue: $M 724Scope 1 Intensity: 25.27 tCO2e/$MDDDa Ren TangYear: 2023Scope 1: 5,902 tCO2eRevenue: $M 1,157Scope 1 Intensity: 5.10 tCO2e/$MCCChina Resources SanjiuYear: 2024Scope 1: 55,312 tCO2eRevenue: $M 3,784Scope 1 Intensity: 14.62 tCO2e/$MCanSino BiologicsYear: 2023Scope 1: 3,541 tCO2eRevenue: $M 49Scope 1 Intensity: 72.91 tCO2e/$M

How does CanSino Biologics's GHG emissions intensity compare to its peers?

In 2023, CanSino Biologics reported a Scope 1 emissions intensity of 72.91 tCO₂e per millions USD. Compared to the peer group median of 23.6, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a

Where does CanSino Biologics rank on GHG emissions intensity within its industry?

In 2023, CanSino Biologics ranked 22 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

This places CanSino Biologics among the least efficient performers, with one of the highest emissions intensities in its sector.a

Want Full Access to CanSino Biologics's GHG Emissions Dataset?
Start 30-Day Free Trial